Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryRefractory/Relapse Acute Myeloid Leukemia
- Interventions
- Drug: Ceramide NanoLiposome (Ceraxa)
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Keystone Nano, Inc
- Target Recruit Count
- 11
- Registration Number
- NCT04716452
- Locations
- 🇺🇸
Penn State University Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Keystone Nano, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT02834611
- Locations
- 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
News
No news found